BCM
BIOT

BCK Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

BCK Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,146
Closed -$268K – 122
2022
Q1 		$268K Buy
+27,146
New +$267K 0.16% 109

Other funds holding BIOT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

BCK Capital Management's BIOT Position: Q2 2022 in Review

BCK Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 27,146 shares — an estimated $268K sold.

BCK Capital Management first reported a position in BIOT in Q1 2022 and held it in 1 quarter. The position peaked at $268K in Q1 2022. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

  • BCK Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • BCK Capital Management sold 27,146 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $268K.
  • BCK Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • BCK Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $268K in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on BCK Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.